Rein Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.24) by 54.17 percent. This is a 94.18 percent increase over losses of $(1.89) per share from the same period last year.